The present invention provides a liquid aqueous formulation for the intranasal administration of apomorphine, which comprises: (a) at least about 15 mg/ml of apomorphine； and (b) a solubilising agent selected from (i) at least one polyoxyethylene-polyoxypropylene copolymer (poloxamer)； (ii) at least one cyclodextrin； and (iii) at least one cyclodextrin together with chitosan. The formulations of the invention can be used in the treatment/management of Parkinson's disease.
